Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX
04:38am, Thursday, 04'th Dec 2025
Fisher Asset Management LLC lowered its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 5.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the
American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX
03:18am, Wednesday, 03'rd Dec 2025
American Century Companies Inc. grew its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 24.7% during the second quarter, according to the company in its most recent filing with the Securitie
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
08:01am, Monday, 10'th Nov 2025
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished
Celldex to Present at Upcoming Investor Conferences
08:01am, Friday, 07'th Nov 2025
HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU
Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
12:20pm, Wednesday, 10'th Sep 2025
Celldex Therapeutics, Inc. (NASDAQ:CLDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Anthony S. Marucci - Founder, President, CEO & Dire
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
09:01am, Tuesday, 09'th Sep 2025
HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stan
Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track
03:45pm, Thursday, 21'st Aug 2025
Celldex Therapeutics, Inc.'s barzolvolimab failed to improve symptoms in eosinophilic esophagitis, but this setback doesn't impact its promising ongoing urticaria programs. Phase 3 trials for chronic
Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
10:22am, Wednesday, 20'th Aug 2025
On Tuesday, Celldex Therapeutics, Inc. CLDX released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
04:01pm, Tuesday, 19'th Aug 2025
HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esoph
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
06:56pm, Thursday, 07'th Aug 2025
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.54 per share a year ago.
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Thursday, 07'th Aug 2025
HAMPTON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2025 and provided a corporate update.
HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Compan
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
06:01pm, Thursday, 12'th Jun 2025
HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months a
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
04:01pm, Tuesday, 10'th Jun 2025
HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company's Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at
